It is essential to acknowledge the rapidly evolving landscape of diabetes management, which has seen the introduction of several new therapeutic options, including GLP‐1 receptor agonists (GLP1RA) and other novel agents. This evidence concerns the gene GLP1R and diabetes mellitus.